跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
优泌林 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Recombinant Human Insulin Injection
Approved
生物制品
Recombinant Human Insulin Injection
LILLY FRANCE
🇨🇳 National Medical Products Administration
Approval Date
Apr 16, 2020
Approval ID
7MazXbMjabn
Company
LILLY FRANCE
Type
生物制品
Approval Details
Approval Id
7MazXbMjabn
Approval Number
S20160057
Generic Name
人胰岛素注射液
Generic Name En
Recombinant Human Insulin Injection
Trade Name
优泌林
Drug Type
生物制品
Dosage Form
注射剂
Strength
3ml:300单位(预装注射笔)
Reg Date
2020-04-16
Expired Date
2025-04-15
Company Name
LILLY FRANCE
Company Address
24 boulevard Vital Bouhot CS 50004 92521 NEUILLY SUR SEINE CEDEX France
Production Company Name
LILLY FRANCE
Production Company Address
Zone Industrielle 2 rue du colonel Lilly 67640 Fegersheim,France
Company Detail Path
/organization/lilly-france
Production Company Detail Path
/organization/lilly-france
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Apr 16, 2020
Approval ID
7MazXbMjabn
Type
生物制品
Back to NMPA Approvals